BioCentury
ARTICLE | Company News

Bind Therapeutics, Affilogic deal

May 16, 2016 7:00 AM UTC

Bind will investigate the use of Affilogic’s Nanofitins targeting immuno-oncology checkpoints as ligand components of Accurins. Bind’s Accurins are polymeric nanoparticle-encapsulated therapeutics engineered to target specific cells and tissues at the site of disease. The surface of Accurin can be functionalized with ligands. Nanofitins are small affinity proteins that can be conjugated to other moieties to increase target-specificity and enable cellular uptake. Upon achievement of proof of concept, Bind hopes to expand the collaboration to develop Accurins that bind immuno-oncology targets. The companies said additional terms are not disclosed. ...